Anagin Inc is a biotechnology startup based in the United States, founded in 2014. The company is focused on developing first-in-class therapies for treating a spectrum of challenging conditions including Post Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI), Depression, Neuropathic Pain, Alzheimer’s disease, and Parkinson's disease. Their innovative approach to addressing these profound medical needs falls within the Biotechnology, Health Care, and Life Sciences industries. Anagin Inc's commitment to tackling complex neurological and psychiatric illnesses presents an opportunity for venture capitalists seeking to invest in the cutting-edge biotech sector. With a strong emphasis on addressing significant unmet medical needs, their potential for impacting the lives of millions is substantial. While details regarding their last investment and associated investors are currently unavailable, Anagin Inc's focus on neurology and psychiatry therapeutics positions them as an intriguing prospect for potential investment opportunities within the rapidly evolving biotech landscape.
There is no investment information
No recent news or press coverage available for Anagin Inc.
We care about your data, and we'd love to use cookies make your experience better.
